国投证券股份有限公司 关于上海雪榕生物科技股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市 规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等有关规定，国投证券股份有限公司（以下简称"国投证券"或"本保荐机构"） 作为上海雪榕生物科技股份有限公司（以下简称"雪榕生物"或"公司"）创业 板向特定对象发行股票的保荐机构，对雪榕生物 2023 年度募集资金存放和使用 情况进行了专项核查，现将核查情况报告如下： 一、募集资金基本情况 经中国证监会《关于同意上海雪榕生物科技股份有限公司向特定对象发行股 票注册的批复》（证监许可【2021】881 号）核准，公司于 2022 年 3 月 4 日向 11 名特定对象发行人民币普通股（A 股）65,676,567 股，发行价格为人民币 6.06 元 /股，募集资金总额为人民币 397,999,996.02 元，扣除与本次发行有关费用人民币 10,519,671.82 元（含增值税）后，实际 ...

二、财务状况、经营成果和现金流量情况分析 上海雪榕生物科技股份有限公司 2023 年度财务决算报告 根据上海雪榕生物科技股份有限公司截止 2023 年 12 月 31 日的财务状况和 2023 年度的经营成果和现金流量，结合公司实际运营中的具体情况，我们进行 了认真的研究分析，现将公司有关的财务决算情况汇报如下： 一、2023 年公司财务报表审计情况 公司 2023 年财务报表已经安永华明会计师事务所（特殊普通合伙）审计， 出具了安永华明（2024）审字第 70009152_B01 号标准无保留意见审计报告。会 计师的审计意见是：公司财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了上海雪榕生物科技股份有限公司 2023 年 12 月 31 日的合并及公司财 务状况以及 2023 年度的合并及公司经营成果和现金流量。 （一）资产情况： | 单位：万元 | | --- | | 项目 | 2023 | 年 12 | | 年 2022 12 | 同比增减 | 占总资产比重 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 月 31 日 | ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-034 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于前期会计差错更正及追溯调整的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于2024年4月25日召开 第五届董事会审计委员会第五次会议、第五届董事会第九次会议和第五届监事会 第七次会议，分别审议通过了《关于前期会计差错更正及追溯调整的议案》，同 意公司根据《企业会计准则第28号——会计政策、会计估计变更和差错更正》《公 开发行证券的公司信息披露编报规则第19号——财务信息的更正及相关披露》等 相关规定和要求，对公司前期会计差错进行更正并追溯调整相关年度的财务数 据。现将具体事项公告如下： 一、前期会计差错更正的原因及内容 （一）前期会计差错更正的原因 公司于2023年12月25日收到中国证券监督管理委员会上海监管局（以下简称 "上海证监局"）印发的《关于对上海雪榕生物科技股份有限公司采取责令改正措 施的决定 ...

Financial Performance - The company achieved operating revenue of CNY 2,062.83 million in 2021, a decrease of 6.33% year-on-year[13]. - The net profit attributable to shareholders was CNY -292.07 million, representing a decline of 226.76% compared to the previous year[13]. - The net profit after deducting non-recurring gains and losses was -¥29.0 million in 2021, a decrease of 230.53% compared to a profit of ¥22.2 million in 2020[30]. - The weighted average return on net assets was -15.88%, a decrease of 28.41% from the previous year[20]. - The company's total assets decreased by 4.57% to CNY 4,340.13 million at the end of 2021[19]. - The net cash flow from operating activities was CNY 246.75 million, down 55.58% from the previous year[20]. - The net profit attributable to shareholders was ¥101.4 million in Q1, but turned negative in subsequent quarters, with Q2 at -¥172.1 million, Q3 at -¥44.7 million, and Q4 at -¥176.7 million[21]. - The net cash flow from operating activities showed a significant recovery, with Q1 at ¥94.2 million, Q3 at ¥19.2 million, and Q4 surging to ¥175.8 million[21]. - The asset-liability ratio increased to 61.88% in 2021 from 55.89% in 2020, indicating a rise of 5.99%[30]. - The EBITDA to total debt ratio fell to 2.43% in 2021 from 23.90% in 2020, reflecting a decline of 21.47%[30]. - The interest coverage ratio dropped significantly to -2.84 in 2021 from 3.28 in 2020, a decrease of 186.59%[30]. Dividend and Shareholder Information - The company reported a cash dividend of 0.00 yuan per 10 shares for all shareholders, with no bonus shares issued, based on a total of 507,600,151 shares[1]. - The top shareholder, Yang Yongping, holds 24.29% of the shares, amounting to 107,365,050 shares[22]. - The company has no preferred shareholders as of the report date[24]. Business Operations and Strategy - The company operates modern agricultural enterprises focused on the research, cultivation, and sales of edible mushrooms, with production facilities in multiple regions including Jilin, Shandong, Guangdong, Sichuan, Guizhou, Gansu, and Thailand[3]. - Key products include Enoki mushrooms, King oyster mushrooms, Shiitake mushrooms, and others, emphasizing high quality and safety in food production[5]. - The sales model primarily involves distributors, with direct sales to supermarkets, chain restaurants, and fresh food delivery platforms, utilizing a buyout sales approach[9]. - The pricing strategy includes weekly market analysis for existing products and comprehensive market research for new product pricing, ensuring competitive positioning[10]. - The company has implemented a credit policy for large and quality customers, resulting in low accounts receivable balances[10]. - The company emphasizes the mechanization, standardization, and year-round production of edible mushrooms, significantly saving land resources[3]. - The company aims to enhance its market presence through continuous product innovation and expansion into new regions[3]. - The company has established a nationwide sales network to enhance market responsiveness and customer retention[17]. - The competitive landscape in the edible mushroom industry has intensified, leading to a general decline in profitability across the sector in 2021[17]. Audit and Compliance - The company has transitioned its auditing firm to Ernst & Young Huaming, receiving a standard unqualified audit opinion for the financial report[1]. Project Losses - The company reported a significant loss of CNY 4,850.09 million from its Thailand project, with a loss attributable to shareholders of CNY 2,910.05 million[13]. Quarterly Performance - In Q1 2021, the company reported revenue of ¥566.5 million, while Q2 revenue dropped to ¥362.3 million, followed by Q3 at ¥500.5 million, and Q4 at ¥633.5 million[21].

Financial Performance - The company's total revenue for 2020 was ¥2,202,185,873.52, representing a 12.09% increase compared to ¥1,964,574,723.12 in 2019[26]. - The net profit attributable to shareholders for 2020 was ¥230,412,693.24, a 4.58% increase from ¥220,327,429.85 in 2019[26]. - The net cash flow from operating activities decreased by 5.36% to ¥555,465,789.24 in 2020 from ¥586,928,417.62 in 2019[26]. - The total assets at the end of 2020 were ¥4,547,783,435.53, an 18.37% increase from ¥3,841,850,151.29 at the end of 2019[26]. - The net assets attributable to shareholders increased by 15.90% to ¥2,017,187,114.89 at the end of 2020 from ¥1,740,475,998.42 at the end of 2019[26]. - The basic earnings per share for 2020 was ¥0.53, up 3.92% from ¥0.51 in 2019[26]. - The diluted earnings per share for 2020 was ¥0.54, a 5.88% increase from ¥0.51 in 2019[26]. - The company reported a quarterly revenue of ¥638,713,309.32 in Q4 2020, showing a strong performance compared to previous quarters[29]. - The company received government subsidies amounting to ¥27,886,368.45 in 2020, which was primarily related to its subsidiary[32]. - The company reported a total distributable profit of RMB 639,642,807.27 for the year[121]. Production and Capacity - The company reported a significant increase in production capacity, leading to intensified competition in the edible mushroom market, which may result in a downward pressure on product prices[6]. - The company has a daily production capacity of 1,325 tons of edible mushrooms, with enoki mushrooms accounting for 1,000 tons, ranking first in the country[45]. - The production capacity of subsidiary companies for king oyster mushrooms and other varieties has been further released, leading to an increase in edible mushroom production and sales volume[40]. - The company has established seven major production bases across China and is constructing additional bases in Hubei and Anhui, enhancing its national layout[45]. - The company has invested in comprehensive edible mushroom factories in various regions, including Shanghai, Jilin, and Thailand, promoting mechanized and standardized production[36]. Market and Sales - The company operates a sales model primarily through distributors, with direct sales to supermarkets, chain restaurants, and fresh delivery platforms[40]. - The edible mushroom sector accounted for ¥2,179,627,097.78, or 98.98% of total revenue, with a year-on-year growth of 12.01%[66]. - The sales of enoki mushrooms generated ¥1,625,784,212.05, making up 73.83% of total revenue, with a growth of 5.66% from the previous year[66]. - Domestic sales contributed ¥2,164,250,122.84, which is 98.28% of total revenue, reflecting an increase of 11.41% year-on-year[63]. - The company has diversified its marketing strategies, increasing its presence in major retail chains and e-commerce platforms[56]. Research and Development - Research and development expenses rose by 8.38% to ¥11,850,052.26, indicating ongoing investment in technology and product development[76]. - The company is focusing on the research and development of new strains and varieties to ensure stable production and improve product quality[112]. - The company has a strategic focus on the "plant-based meat" sector, with ongoing research and development efforts[118]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new technologies and products in 2021[166]. Risk Management - The company anticipates potential risks of declining gross margins due to increased competition and price reductions in the edible mushroom market, alongside challenges in overseas operations[9]. - The main raw materials for production include rice bran, corn husks, and other agricultural by-products, which are subject to price volatility and quality fluctuations that could impact production costs[10]. - Management risks associated with business expansion are being addressed through the implementation of a partner mechanism to improve management efficiency and team motivation[12]. Investment and Expansion - The company has signed investment agreements to build new production bases in Hubei and Anhui, further consolidating its market position[57]. - The company has established new subsidiaries in Thailand and China in 2020, reflecting the company's strategy for market expansion[71]. - The company is actively seeking investment opportunities and potential mergers and acquisitions in the edible mushroom industry to explore new growth avenues[112]. Cash Dividends and Shareholder Returns - The company has proposed a cash dividend of 1.2 RMB per 10 shares, based on a total of 442,029,925 shares[13]. - The cash dividend amount for 2020 was 53,043,591.0, representing 23.02% of the net profit attributable to ordinary shareholders[125]. - The cash dividend represents 100% of the total profit distribution for the year[121]. - The company plans to distribute cash dividends amounting to no less than 20% of the distributable profit achieved in the current year[159]. Compliance and Governance - The company has not classified any non-recurring gains as recurring gains in its financial reporting[33]. - The company has not experienced any major litigation or arbitration matters during the reporting period[183]. - The company has not engaged in any related party transactions during the reporting period[186]. - The company has a commitment to not transfer shares exceeding 25% of their total holdings during their tenure[126]. Sustainability and Future Outlook - The company emphasizes the importance of reasonable returns to investors while ensuring sustainable development[158]. - A commitment to sustainability has been made, with plans to reduce carbon emissions by 15% over the next three years[141]. - The company plans to enhance its marketing network and develop new edible mushroom products to strengthen its competitive edge[110]. - Looking ahead, the company has provided guidance for 2021, projecting a revenue growth of 30% to 1.56 billion yuan[140].

Financial Performance - In 2023, the company achieved operating revenue of CNY 2,565.14 million, a year-on-year increase of 10.55%, while the net profit attributable to shareholders was a loss of CNY 188.06 million[5]. - The company's operating revenue for 2023 reached ¥2,565,144,194.86, representing a 10.55% increase compared to ¥2,320,432,033.82 in 2022[40]. - The net profit attributable to shareholders for 2023 was ¥188,062,576.34, a decrease of 34.52% from ¥287,226,615.66 in 2022[40]. - The net cash flow from operating activities was ¥357,835,977.19, showing a slight decrease of 2.53% from ¥367,133,291.06 in 2022[40]. - The total assets at the end of 2023 amounted to ¥4,602,166,751.34, an increase of 13.02% from ¥4,072,032,070.00 at the end of 2022[40]. - The total revenue for the year 2023 was approximately RMB 2.35 billion, representing a year-on-year increase of 13.47% compared to RMB 2.07 billion in 2022[79]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, with a total of ¥194,869,834.70 in 2023 compared to ¥310,590,426.00 in 2022, a decrease of 37.26%[40]. Market and Competition - The competitive landscape in the edible mushroom industry has intensified, leading to a downward pressure on product prices due to increased production capacity from competitors[10]. - The company anticipates that the increased supply of edible mushrooms may lead to short-term imbalances in supply and demand, affecting sales prices in the near future[10]. - The company plans to enhance its marketing efforts and improve product quality to maintain market share amid rising competition and price pressures[13]. - The edible mushroom industry in China has seen a decline in the number of factory production enterprises, decreasing from 417 in 2019 to 337 by the end of 2021, a reduction of nearly 20%[52]. - The company is expanding its market presence in Southeast Asia by establishing trade companies in Vietnam and Malaysia[72]. Production and Capacity - The company has a daily production capacity of 1,710 tons of edible mushrooms, with 1,275 tons of that being enoki mushrooms, ranking first in the country[53]. - The company is focusing on expanding production capacity in response to market demand, with several projects, including a 120,000-ton modern agricultural industrial park in Guangxi and a 53,000-ton enoki mushroom project in Fujian, coming online[52]. - The company plans to expand its production capacity and operational scale while maintaining key production indicators for edible mushrooms, which poses a risk to management efficiency and requires a robust management system[20]. Financial Management and Risks - The company is facing risks related to raw material price fluctuations, which could impact production costs and overall profitability if not managed effectively[14]. - The company's liquidity position is under scrutiny, with current liabilities exceeding current assets by CNY 1.346 billion, but it maintains the ability to secure financing through established credit lines[11]. - The company has acknowledged accounting errors in previous years, leading to restatements of financial data for 2020-2022, as mandated by regulatory authorities[40]. - The company has implemented a unified procurement model for raw materials, reducing reliance on suppliers and optimizing costs[63]. Research and Development - The company holds 59 patents, including 21 invention patents, and has been recognized for its technological advancements in mushroom production[68]. - The company is actively involved in research and development, being selected as a key laboratory for edible mushroom strain research by the Ministry of Agriculture and Rural Affairs[68]. - The company aims to enhance the activity of mushroom strains through its ongoing R&D project, which is expected to strengthen its core competitiveness in the market[87]. - The total R&D investment for 2023 was CNY 8,139,486.19, maintaining a ratio of 0.32% of operating revenue, consistent with 2022[91]. Governance and Compliance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, ensuring independent operations from its controlling shareholders[120]. - The board of directors consists of 7 members, including 3 independent directors, meeting legal and regulatory requirements[121]. - The company has not provided guarantees for its controlling shareholders and has maintained independence in its operations[120]. - The company has committed to timely and accurate information disclosure, ensuring equal access for all shareholders[124]. Employee Management - The total number of employees at the end of the reporting period was 2,513, with 198 in the parent company and 2,315 in major subsidiaries[155]. - The employee composition includes 1,612 production personnel, 99 sales personnel, 406 technical personnel, 66 financial personnel, and 330 administrative personnel[155]. - The company has established a dual-channel talent development system focusing on general and elite talent to enhance employee capabilities[159]. - The company emphasizes a fair and competitive salary system based on performance, efficiency, and fairness principles[157]. Environmental and Social Responsibility - The company has invested in poverty alleviation initiatives, building edible mushroom precision poverty alleviation industrial parks in Guizhou and Gansu, contributing to local economic development[184]. - The company continues to prioritize employment for poverty-stricken households, providing training and guidance to enhance labor skills and improve local employment conditions[185]. - The company has implemented a comprehensive environmental management system that meets regulatory requirements, with no reported administrative penalties for environmental issues during the reporting period[182]. Shareholder Engagement - The company held several shareholder meetings in 2023, with participation rates of 29.07% for the first temporary meeting and 25.35% for the annual meeting[128]. - The company has proposed a restricted stock incentive plan during the meeting on August 23, 2023[151]. - The company has committed to not transferring more than 25% of its directly or indirectly held shares during its tenure, with a lock-up period of 12 months following the IPO date[188].

上海雪榕生物科技股份有限公司 2021 年半年度报告摘要 证券代码：300511 证券简称：雪榕生物 公告编号：2021-089 债券代码：123056 证券简称：雪榕转债 上海雪榕生物科技股份有限公司 2021 年半年度报告摘要 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者应当到证监会指 定媒体仔细阅读半年度报告全文。 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议 | 未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | --- | --- | --- | --- | | 非标准审计意见提示 | | | | | □ 适用 √ 不适用 | | | | | 董事会审议的报告期普通股利润分配预案或公积金转增股本预案 | | | | | □ 适用 √ 不适用 | | | | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | | 董事会决议通过的本报告期优先股利润分配预案 | | | | | □ 适用 √ 不适用 | | | | 二、公司基本情况 1、公司简介 | 股票简称 ...

上海雪榕生物科技股份有限公司 2021 年第三季度报告 证券代码：300511 证券简称：雪榕生物 公告编号：2021-106 证券代码：300511 证券简称：雪榕生物 上海雪榕生物科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明： 保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 500,488,155.72 | -11.84% | 1,429,298,969.19 | -8.58% | | 归属于上市公司股东 的净利润（元） | -44,687,522.97 | -1 ...

上海雪榕生物科技股份有限公司 2021 年第一季度报告全文 上海雪榕生物科技股份有限公司 2021 年第一季度报告 2021 年 04 月 1 上海雪榕生物科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨勇萍、主管会计工作负责人陈雄及会计机构负责人(会计主管 人员)陈雄声明：保证季度报告中财务报表的真实、准确、完整。 2 上海雪榕生物科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | 支付的优先股股利 | 0.00 | | --- | --- | | 用最新股本计算的全面摊薄每股收益（元/股） | 0.2293 | 非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提 ...

2023 年度独立董事述职报告 上海雪榕生物科技股份有限公司 一、独立董事的基本情况 各位股东及股东代表： 本人刘浩，在2023年度任职上海雪榕生物科技股份有限公司（以下简称"公 司"）独立董事期间，严格按照《公司法》《深圳证券交易所上市公司自律监管 指引第2号——创业板上市公司规范运作》等法律法规、规范性文件以及《公司 章程》《公司独立董事工作制度》的规定和要求，认真、勤勉、独立的履行独立 董事职责，主动了解公司的生产经营运作情况，积极出席公司召开的相关会议， 认真审议董事会的各项议案，充分发挥了独立董事的独立性、专业性的作用，切 实维护了公司和全体股东尤其是中小股东的合法权益。现将本人2023年度任职期 间履行独立董事职责情况汇报如下： （一）个人工作履历、专业背景等情况 刘浩，男，1978年11月生，中国国籍，无境外永久居留权，博士学历，教授 职称。曾任上海财经大学会计学院讲师、副教授，美国纽约城市大学访问学者， 2017年8月至2023年8月任公司独立董事。现任上海财经大学会计学院教授、博士 生导师，财政部第四届企业会计准则咨询委员会委员。兼任上海肇民新材料科技 股份有限公司、湖北回天新材料股份有限公 ...